# Aegle Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aegle-therapeutics

- Industry: Healthcare Specialists
- Headquarters: Miami, US
- Website: www.aegletherapeutics.com
- Total disclosed funding: $11M
- Latest round: Series A (Sep 29, 2020)
- Investors on record: 5

## About

Aegle Therapeutics Corp. is focused on regenerative medicine, developing advanced extracellular vesicle therapies to treat rare diseases, particularly dystrophic epidermolysis bullosa and severe dermatological disorders.Aegle Therapeutics Corp., founded in 2019 and headquartered in Miami, US, specializes in developing innovative therapies using extracellular vesicles (EVs). The company is led by CEO Shelley Hartman. Aegle has secured a total of USD 6.5 mn through its Series A funding round in September 2020, with investors including DEFTA Partners, DeepWork Capital, New World Angels, and Tellus BioVentures. The company has engaged in a total of 3 deals, focusing on clinical trials for their leading product, AGLE-102.Aegle Therapeutics specializes in regenerative medicine by developing innovative extracellular vesicle (EV) therapies aimed at treating debilitating rare diseases, particularly dystrophic epidermolysis bullosa (DEB) and other severe dermatological disorders. Their core product, AGLE-102, is a therapeutic composite of EVs, including exosomes derived from mesenchymal stem cells (MSCs), which utilize proprietary EV harvesting technology. This product is designed to deliver biomolecular payloads capable of stimulating cellular functions and promoting healing in affected individuals. The company’s clinical-stage offerings are targeted primarily at patients with significant unmet medical needs in North America and Europe, with an active phase 1/2 clinical study for AGLE-102 currently open for enrollment among individuals living with Recessive Dystrophic Epidermolysis Bullosa (RDEB). The ultimate goal of Aegle Therapeutics is to improve the quality of life for patients suffering from these rare conditions through their advanced therapeutic platforms.Aegle Therapeutics operates within a clinical development framework, focusing on the commercialization of its EV-based therapies. Revenue generation occurs primarily through partnerships with healthcare providers, hospitals, and research institutions engaged in clinical trials and subsequent product implementations. Given the clinical nature of their offerings, transactions typically involve agreements structured around clinical trial sponsorships and potential future sales of AGLE-102 upon successful completion of regulatory pathways. As the company progresses through its clinical trials and works towards market launch, it anticipates revenue streams would primarily arise from direct engagements with healthcare institutions, potentially accompanied by future collaborations with pharmaceutical companies for broader distribution. The financial structure of these transactions would ensure alignment with clinical outcomes and successful market entry for their flagship product, AGLE-102.Aegle Therapeutics plans to leverage its recent Series A funding of USD 6.5 mn raised in September 2020 to support its clinical development and product expansion initiatives. The company is focused on advancing its clinical trials for AGLE-102 and aims to broaden its reach into North America and Europe, targeting specific healthcare institutions for collaborations by 2022. The funding will facilitate the continuation of clinical trial processes and the establishment of strategic partnerships that are critical for bringing AGLE-102 to market.

## Funding rounds

- Series A, Sep 29, 2020, $6.5M — DEFTA Partners, New World Angels, DeepWork Capital, Tellus BioVentures
- Series A, Dec 31, 2019, $4M — DEFTA Partners, New World Angels, DeepWork Capital, Ocean Azul Partners, Tellus BioVentures

## Investors

- DEFTA Partners (https://capitalatlas.ai/funds/defta-partners) — Series A
- New World Angels (https://capitalatlas.ai/funds/new-world-angels) — Series A
- DeepWork Capital (https://capitalatlas.ai/funds/deepwork-capital) — Series A
- Ocean Azul Partners (https://capitalatlas.ai/funds/ocean-azul-partners) — Series A
- Tellus BioVentures (https://capitalatlas.ai/funds/tellus-bioventures) — Series A